Citation

Nasir M, Andrew Grant J. Clinical Medicine Insights: Therapeutics 2011; 3: 379-394.

Copyright

(Copyright © 2011)

DOI

10.4137/CMT.S6375

PMID

unavailable

Abstract

Allergic rhinitis is a common, chronic medical condition affecting millions of people worldwide. Uncontrolled disease has been associated with impairments in quality of life and decreased economic productivity. Proper identification and control of relevant co- morbid conditions is essential for optimal rhinitis control. Management of allergic rhinitis includes identification of relevant allergens, education on avoidance measures, medications and immunotherapy. First-line therapy includes the use on an intranasal steroid. Other treatment options include oral or intranasal antihistamines, decongestants, leukotriene receptor antagonists, mast cell stabilizers or anticholinergic agents. Immunotherapy is an effective treatment option for refractory disease. © the author(s), publisher and licensee Libertas Academica Ltd.

Language: en

Keywords

human; insomnia; suicidal ideation; depression; suicide attempt; patient education; review; fatigue; driving ability; sedation; physical examination; avoidance behavior; urine retention; constipation; drug mechanism; gastrointestinal symptom; steroid; confusion; drug safety; placebo; cerebrovascular accident; learning disorder; drug efficacy; tremor; cost effectiveness analysis; antihistaminic agent; corticosteroid; unindexed drug; cardiovascular disease; hypertension; side effect; cholinergic receptor blocking agent; pruritus; allergic rhinitis; loratadine; montelukast; anticholinergic effect; hay fever; child death; heart palpitation; angioneurotic edema; dizziness; drug eruption; treatment response; unspecified side effect; systemic disease; cetirizine; nose congestion; nose mucus; drug induced headache; adrenal suppression; anaphylaxis; fluticasone propionate; Immunotherapy; ischemic optic neuropathy; blurred vision; application site burning; epistaxis; mometasone furoate; daytime somnolence; decongestive agent; blood brain barrier; absence of side effects; prednisone; control strategy; histamine H1 receptor antagonist; drug protein binding; allergen; cytokine release; bedtime dosage; throat irritation; taste; pet animal; glucocorticoid receptor; oxymetazoline; xylometazoline; fexofenadine; mucosal dryness; leukotriene receptor blocking agent; swelling; ipratropium bromide; dry nose; beclometasone dipropionate; nose irritation; azelastine; fluticasone furoate; perennial rhinitis; cromoglycate disodium; omalizumab; application site irritation; patient preference; perioperative period; hypertransaminasemia; allergic asthma; Allergic rhinitis; Antihistamines; application site rash; Avoidance measures; bitter taste; branch retinal artery occlusion; claritin D; cockroach; house dust allergen; injection site stinging; Intranasal steroids; leukotriene C4; metallic taste; nose septum perforation; pollen antigen; skin test; subcutaneous immunotherapy; sublingual immunotherapy